freeze-thaw cycle comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-01. Numbers and descriptions here follow the published literature rather than marketing material.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
==== MeSH D12.125.068 – amino acids, basic ==== MeSH D12.125.068.050 – arginine MeSH D12.125.068.050.075 – argininosuccinic acid MeSH D12.125.068.050.095 – benzoylarginine-2-naphthylamide MeSH D12.125.068.050.100 – benzoylarginine nitroanilide MeSH D12.125.068.050.400 – homoarginine MeSH D12.125.068.050.525 – ng-nitroarginine methyl ester MeSH D12.125.068.050.587 – nitroarginine MeSH D12.125.068.050.650 – omega-n-methylarginine MeSH D12.125.068.050.900 – tosylarginine methyl ester MeSH D12.125.068.060 – asparagine MeSH D12.125.068.330 – glutamine MeSH D12.125.068.330.700 – proglumide MeSH D12.125.068.555 – lysine MeSH D12.125.068.555.478 – hydroxylysine MeSH D12.125.068.555.575 – lysinoalanine MeSH D12.125.068.555.750 – polylysine MeSH D12.125.068.665 – ornithine MeSH D12.125.068.665.340 – eflornithine
== History == The introduction and use of ampicillin alone started in 1961. The development and introduction of this drug allowed the use of targeted therapies against gram-negative bacteria. With the rise of beta-lactamase producing bacteria, ampicillin and the other penicillin-derivatives became ineffective to these resistant organisms. With the introduction of beta-lactamase inhibitors such as sulbactam, combined with ampicillin made beta-lactamase producing bacteria susceptible.
==== Bioengineered RNA agents to study miRNA function and replacement therapy ==== A longstanding limitation in miRNA research has been the reliance on chemically synthesized miRNA mimics or biosimilars, which bear extensive non-natural chemical modifications—including altered ribose subunits and backbone linkages—whose physiochemical and biological properties may not faithfully recapitulate those of endogenous, genome-derived miRNA species. While chemical modifications may improve metabolic stability and binding affinity, their inclusion introduces structural divergence from natural miRNA and may increase immunogenic risk, raising questions about how accurately commercial mimics model endogenous miRNA biology. To address these concerns, RNA molecular bioengineering platforms have been developed that produce recombinant miRNA molecules—termed bioengineered RNAs (BioRNAs)—through in vivo fermentation in bacteria using human transfer RNA (htRNA) fused precursor miRNA carriers. This approach yields agents with high purity, low endotoxin content, and structural and chemical properties that more closely represent those of naturally processed, endogenous miRNA, including post-transcriptional modifications acquired during biogenesis in living cells. BioRNA agents have been produced successfully across a diverse panel of miRNA sequences and have demonstrated functional equivalence to or improvement over commercial LNA mimics in regulating target gene expression—including known cancer-relevant targets such as EGFR, MRP1, and VDAC1—in human cancer cell lines.
== Function == Exercise causes increased expression in muscle of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1alpha), which is involved in adaptation to exercise. In mice, this causes production of the FNDC5 protein which is cleaved to give a new product irisin. Due to its production through a mechanism initiated by muscular contraction, irisin has been classified as a myokine.
== Structure == The party president is the top position of SWAPO; in 2012 this was held by Namibia's former president Pohamba. The vice-president was Namibia's former president Hage Geingob, who was elected to that position in 2007 and reconfirmed at the SWAPO congress in December 2012, until his death on 4 February 2024. The third highest position in SWAPO is the secretary-general, a position held in December 2012 by Nangolo Mbumba. Number four is the deputy secretary-general, Omaheke governor Laura McLeod-Katjirua. Like many socialist and communist parties, SWAPO is governed by a politburo and a central committee. The party leadership is advised by a youth league, a women's council, and an elders' council.
Sources: en.wikipedia.org
His position has mostly been met with negative comments across the media and sports press due to the NFL having as many as 4,500 former players reporting symptoms of CTE. More recently, he has been investigating the therapeutic effects of hyperbaric oxygen therapy (HBO) in various neurological conditions, including post-concussion syndrome, PTSD, traumatic brain injury, stroke, and spinal cord injury. Maroon was asked to testify to the New York City Council on a proposed rule on sideline medical coverage for organized youth football in the city. Together with Russell Blaylock, he developed an inflammation hypothesis for the biochemical mechanisms involved in the development of CTE following head trauma. In the 2015 movie Concussion, which "examines how American football players suffer from major head injuries and life-long debilitating problems as a result of repeated concussions, and efforts by the National Football League to deny it," Maroon was played by actor Arliss Howard. In the movie, Maroon is portrayed as an NFL-biased doctor who tries to deny any relationship between football concussions and the brain pathology that Dr. Bennet Omalu found and attributed to CTE. Since the release of the movie, several people have come forward in defense of Maroon, stating that his portrayal in the movie is sensationalized and incorrect.
== External links == Interview with Aaron Klug, Nobel Laureate for structural elucidation of biologically important nucleic-acid protein complexes provided by the Vega Science Trust. Nucleic Acids Research journal Nucleic Acids Book (free online book on the chemistry and biology of nucleic acids) Visualization of nucleotide sequence
Staley's mother, Nancy McCallum, told The Seattle Times in 2007 that despite his isolation, he was never far from the love of his family and friends, who filled his answering machine and mailbox with messages and letters. "Just because he was isolated doesn't mean we didn't have sweet moments with him." McCallum has also claimed that she saw Staley on Thanksgiving of 2001, and again just around Valentine's Day of 2002, when he visited his sister's baby. This was the last time that McCallum saw her son. Sean Kinney has commented on Staley's final years and isolation period:
Joseph Stalin initially resisted Lenin's proposal but ultimately accepted it, and with Lenin's agreement he changed the name to the Union of Soviet Socialist Republics (USSR), although all republics began as socialist soviet and did not change to the other order until 1936. In addition, in the regional languages of several republics, the word council or conciliar in the respective language was only quite late changed to an adaptation of the Russian soviet and never in others, e.g. Ukrainian SSR. СССР (in the Latin alphabet: SSSR) is the abbreviation of the Russian-language cognate of USSR, as written in Cyrillic letters. The soviets used this abbreviation so frequently that audiences worldwide became familiar with its meaning. After this, the most common Russian initialization is Союз ССР (transliteration: Soyuz SSR) which essentially translates to Union of SSRs in English. In addition, the Russian short form name Советский Союз (transliteration: Sovyetsky Soyuz, which literally means Soviet Union) is also commonly used, but only in its unabbreviated form. Since the start of the Great Patriotic War at the latest, abbreviating the Russian name of the Soviet Union as СС has been taboo, the reason being that СС as a Russian Cyrillic abbreviation is associated with the infamous Schutzstaffel of Nazi Germany, as SS is in English. One apparent exception was the Russian abbreviation of the Communist Party of the Soviet Union, КПСС (transliteration: KPSS). In English-language media, the state was referred to as the Soviet Union or the USSR.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.